Avilar Therapeutics
Avilar Therapeutics is a preclinical biopharmaceutical company developing ATAC and MTAC extracellular protein degraders, bifunctional small molecules that harness endolysosomal pathways to eliminate disease-causing extracellular proteins. The company targets indications in women's health (preeclampsia), autoimmune and neurological disease, and cardiometabolic disease.
- Company typePrivate
- Founded2021
- HeadquartersWaltham, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Avilar Therapeutics does
Avilar Therapeutics is a private, preclinical-stage biopharmaceutical company developing a new class of extracellular protein degraders. The company's core ATAC (ASGPR Targeting Chimeras) platform engineers bifunctional small molecules that bind disease-causing proteins in circulation and shuttle them via the asialoglycoprotein receptor on hepatocytes to the endolysosome, where they are degraded. Avilar has extended this modality with the MTAC (M6PR Targeting Chimera) platform, which uses mannose 6-phosphate receptor ligands to target non-hepatocyte membrane proteins, broadening the addressable target universe beyond hepatocyte-restricted biology. The company has demonstrated dose-dependent extracellular protein degradation exceeding 80% in non-human primate studies for IgG and has issued foundational IP covering its ASGPR ligand chemistry.
Avilar's pipeline spans three therapeutic verticals: women's health (lead indication preeclampsia, targeting sFlt1 to extend pregnancy), autoimmune and neurological disease (oral IgG ATACs for IgG autoantibody-driven disease and Anti-MAG Neuropathy), and cardiometabolic disease (oral ApoB ATAC targeting LDL, Lp(a), and triglyceride-rich lipoproteins for atherosclerotic cardiovascular disease). The company emphasizes oral, small-molecule degraders with potential for personalized dosing and rapid onset of action in acute settings.
The business model is licensing- and partnership-driven. As a pre-revenue biotech, Avilar intends to monetize through pharmaceutical partnerships, co-development, licensing, and milestone payments as programs advance, with potential eventual direct commercialization upon regulatory approval. The company was founded in November 2021 by RA Capital Management out of its RAVen incubator with a $60 million seed round, expanded in February 2023 to $75 million with Sanofi Ventures, Medical Excellence Capital, and Astellas Venture Management. The company is headquartered in Waltham, Massachusetts, and operates with 11-50 employees under a leadership team that includes repeat biotech entrepreneurs and inventors of multiple approved drugs.
Avilar Therapeutics firmographics
Firmographics- Name
- Avilar Therapeutics
- Legal name
- Avilar Therapeutics, Inc.
- Website
- https://avilar-tx.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Avilar Therapeutics is a preclinical biopharmaceutical company developing ATAC and MTAC extracellular protein degraders, bifunctional small molecules that harness endolysosomal pathways to eliminate disease-causing extracellular proteins. The company targets indications in women's health (preeclampsia), autoimmune and neurological disease, and cardiometabolic disease.
- Ownership category
- akta.pro rank
Avilar Therapeutics industry classification
Industry- Product category
- Targeted Protein Degradation Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
- akta.pro secondary industries
- RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI), RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target) (HLAAADAI)
Keywords
Where Avilar Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Waltham
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Avilar Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Therapeutic Development and Commercialization: Pre-revenue biopharmaceutical company developing extracellular protein degrader therapeutics. Revenue will be generated through eventual product sales following regulatory approval, as well as potential partnership deals, licensing agreements, and milestone payments during development.
- Partnership and Collaboration Deals: Strategic partnerships with pharmaceutical companies for co-development, licensing, or acquisition opportunities as pipeline programs advance through clinical development stages.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
Avilar Therapeutics product offering
Product offeringCore offering
Avilar Therapeutics is a biopharmaceutical company developing ATACs (ASGPR Targeting Chimeras) and MTACs (M6PR Targeting Chimeras), a novel class of bifunctional small molecule degraders that harness natural endolysosomal pathways to eliminate disease-causing extracellular and membrane-bound proteins. The company uses a modular, integrated drug discovery platform with proprietary high-affinity ASGPR and M6PR ligand chemistry to create first-in-class protein degrader therapeutics for autoimmune, neurological, cardiometabolic, and women's health indications. Pipeline programs include candidates targeting IgG for autoimmune diseases, ApoB for cardiovascular disease, and sFlt1 for preeclampsia.
Differentiator
Problem solved
Functional benefit
Products and services
- ATAC (ASGPR Targeting Chimera) Platform Proprietary platform of bifunctional small molecule degraders using high-affinity ASGPR ligands and modular protein-targeting ligands to shuttle disease-causing extracellular proteins from circulation to the endolysosome for degradation. Used to design and assemble ATACs targeting a wide array of extracellular proteins across autoimmune, neurological, cardiometabolic, and women's health indications.
- MTAC (M6PR Targeting Chimera) Platform Platform leveraging high-affinity small molecule ligands to the mannose 6-phosphate receptor (M6PR) to create MTACs that degrade non-hepatocyte membrane proteins, extending Avilar's degrader reach beyond hepatocytes with monovalent designs, lower molecular weight, and improved physicochemical properties.
- ATAC Program for Preeclampsia (sFlt1 Degrader)
Quantifiable outcome
- 85% reduction in IgG demonstrated in non-human primate repeat-dose study with subcutaneous monovalent ATAC
- +2 more outcomes
Companies that use Avilar Therapeutics
Customer profileSegments3 records
Ideal customer profiles2 records
Avilar Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Avilar Therapeutics partnerships and signals
Strategic signalScale indicators5 records
Recent moves8 records
Expansion highlights5 records
Avilar Therapeutics competitors and assessment
Company assessmentDirect peers
- Lycia Therapeutics: Lycia Therapeutics is a direct competitor developing LYTACs (lysosome-targeting chimeras) for extracellular protein degradation. Both companies pursue bifunctional degraders that route disease-causing extracellular proteins to the endolysosome, making them the closest direct peers in the emerging extracellular protein degradation category.
Broad incumbents
- Arvinas: Arvinas is the pioneer and public clinical-stage leader in targeted protein degradation via PROTACs. While focused on intracellular targets, Arvinas is a benchmark for degrader modality development, has validated the broader protein degradation thesis, and competes for the same investor and pharma partner mindshare as Avilar.
- Kymera Therapeutics: Kymera is a clinical-stage biotech developing heterobifunctional degraders (Pegasus platform) for intracellular targets across immunology and oncology. Kymera's pipeline breadth and clinical progress make it a broad incumbent in the protein degradation space adjacent to Avilar's extracellular focus.
- Nurix Therapeutics: Nurix is a clinical-stage company developing bifunctional degraders (DELTAC platform) for both targeted protein degradation and E3 ligase modulation. As an established player in the broader degrader space, Nurix competes for the same talent, capital, and pharma partnerships as Avilar.
- C4 Therapeutics: C4 Therapeutics is a clinical-stage biotech developing bifunctional degraders (TORPEDO platform) for oncology and other indications. It is an established incumbent in targeted protein degradation competing for pharma partnerships and degrader talent.
Emerging players
- Monte Rosa Therapeutics: Monte Rosa is a clinical-stage biotech developing molecular glue degraders for intracellular targets in oncology and autoimmune disease. While focused on a different degrader modality (glues vs. bifunctional chimeras) and target space, it competes in the broader protein degradation ecosystem and for similar investor/pharma attention.
- Amphista Therapeutics: Amphista is an emerging European biotech developing next-generation targeted protein degraders using novel E3 ligase mechanisms. While targeting intracellular proteins, its platform-based approach and focus on expanding the degradable target universe are conceptually similar to Avilar's modality-expansion strategy.
- Foghorn Therapeutics: Foghorn is a clinical-stage biotech using its Gene Traffic Control platform to develop therapeutics against chromatin regulatory targets, including via degrader approaches. Strategic finance leadership previously came from Foghorn (Tess Cameron), and both companies share the RA Capital backing and early-stage Boston-area biotech ecosystem.
- Jnana Therapeutics: Jnana Therapeutics is a Boston-area biotech developing small molecule drugs for immunology and other diseases. Avilar's CEO Joel Barrish co-founded Jnana, and both companies share RA Capital backing and the Boston biotech ecosystem, though Jnana pursues a different drug modality (allosteric small molecules).
- Frontier Medicines: Frontier Medicines is a preclinical-stage biotech developing chemoproteomics-enabled targeted therapeutics including protein degraders for previously undruggable targets. Both companies are platform-driven degrader companies at similar stages seeking to expand the druggable proteome.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Avilar Therapeutics social profiles
Digital presenceAvilar Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Avilar Therapeutics leadership team
Management profileNumber of profiles
Profiles16 records
Avilar Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Avilar Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Avilar Therapeutics
What does Avilar Therapeutics do?
Avilar Therapeutics is a biopharmaceutical company developing ATACs (ASGPR Targeting Chimeras) and MTACs (M6PR Targeting Chimeras), a novel class of bifunctional small molecule degraders that harness natural endolysosomal pathways to eliminate disease-causing extracellular and membrane-bound proteins. The company uses a modular, integrated drug discovery platform with proprietary high-affinity ASGPR and M6PR ligand chemistry to create first-in-class protein degrader therapeutics for autoimmune, neurological, cardiometabolic, and women's health indications. Pipeline programs include candidates targeting IgG for autoimmune diseases, ApoB for cardiovascular disease, and sFlt1 for preeclampsia.
Is Avilar Therapeutics a public or private company?
Avilar Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Avilar Therapeutics founded?
Avilar Therapeutics was founded in 2021. It employs 11 to 50 people.
Where is Avilar Therapeutics based?
Avilar Therapeutics is headquartered in Waltham, United States, in the North America region.
How does Avilar Therapeutics make money?
Two revenue lines are on record. Therapeutic Development and Commercialization is the primary driver. The others are partnership and Collaboration Deals.
Who are Avilar Therapeutics's main competitors?
Lycia Therapeutics is listed as a direct peer. Broad incumbents are Arvinas, Kymera Therapeutics, Nurix Therapeutics and C4 Therapeutics. Emerging players are Monte Rosa Therapeutics, Amphista Therapeutics, Foghorn Therapeutics, Jnana Therapeutics and Frontier Medicines.
Does Avilar Therapeutics have an API?
No public API is recorded for Avilar Therapeutics.
What industry is Avilar Therapeutics in?
Avilar Therapeutics's product category is Targeted Protein Degradation Therapeutics. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 325414 and its SIC code is 2836.